Who we are
With a multidisciplinary approach on bio-organic chemistry, medicinal & bio-conjugates chemistry, site specific conjugation, our team rich of a wide diversity of scientific profiles and personalities, can also rely on a first order excellence network, both on academic & industrial side, which is regularly enriched by collaborative R&D programs and strategic alliances.
Aiming to maintain long-term relationships with our customers, being closer to their needs, we believe in innovation and pay particular attention to answer specific needs by providing customized solutions with high quality standards.
Techno-provider
Our technologies and know-how guarantee the homogeneity and the stability of your products and the repeatability of your processes.
PROPRIETARY TECHNOLOGY
Antibody Drug Conjugates: DAR 1 / DAR 2 / DAR 4
Site-Specific
DAR Control
Native antibody
Reproducible processOWN R&D
Chemical Tools for Bio-Conjugates & Selective Synthesis
Antibody Drug Conjugates
Our values
• Scientific rigor
Our evidence-based approach is key to creating the next-generation products of medicine.
• Enthusiasm
We know that we are moving towards safer and more efficient therapies for patients.
• Solidarity
We want to develop treatments for diseases that touch everyone’s life.
• Passion
We believe in the potential of our work to change lives.
Our commitment
Illness is something that touches everyone’s life at some point, and our researchers are no exception to this. It is easy for us to be passionate in our work when we are involved in medical breakthroughs that have the potential to one day treat our families and our friends. We are excited to participate in the development of new solutions to improve patient quality of care, to support doctors in the optimization of treatment, and to give patients the best possible chance to fight disease. Our dedication, energy, and hard work comes from our commitment to this goal.
#connected to medical need
Our vision
Our innovations in the field of ADCs have inspired us to contribute to the continued improvement of this cancer treatments, as well as extending the use of ADCs beyond oncology in the near future. We are proud that our work is synonymous with scientific and medical progress to improve patient service and increase quality of care.
#connected to innovation
Our mission
Through our passion and our entrepreneurial spirit, we are dedicated to the discovery and development of new solutions to fight diseases, create new drugs, improve patient quality of life, and ensure a healthier future for people.
#connected to a healthy future




McSAF Inside® Oncology selected in the Top100 of start-up to fund in 2021
McSAF Inside® Oncology, with its drug development project…


Press Release: The European Patent Office has granted McSAF a patent for DAR 4 antibody-drug conjugates technology
Tours, France – 25/02/2021- The European Patent Office…

McSAF recrute un(e) Technicien(ne) R&D
Intéressé par ce poste?
Suivez ce lien :

Meet us at next World ADC Summit, London, 5-6th March 2019
McSAF's team will be attending next World ADC Summit Europe,…

Meet us at 5th Antibody Industrial Symposium, June 27-28, Tours – France
McSAF is presenting at the 5th Antibody Industrial Summit, co-organized…